Literature DB >> 22985069

Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.

Fei Meng1, Jing Hou, Yong-Xian Shao, Pei-Ying Wu, Manna Huang, Xinhai Zhu, Yonghong Cai, Zhe Li, Jie Xu, Peiqing Liu, Hai-Bin Luo, Yiqian Wan, Hengming Ke.   

Abstract

A new series of phosphodiesterase-9 (PDE9) inhibitors that contain a scaffold of 6-amino-pyrazolopyrimidinone have been discovered by a combination of structure-based design and computational docking. This procedure significantly saved the load of chemical synthesis and is an effective method for the discovery of inhibitors. The best compound 28 has an IC(50) of 21 nM and 3.3 μM, respectively, for PDE9 and PDE5 and about 3 orders of magnitude of selectivity against other PDE families. The crystal structure of the PDE9 catalytic domain in complex with 28 has been determined and shows a hydrogen bond between 28 and Tyr424. This hydrogen bond may account for the 860-fold selectivity of 28 against PDE1B, in comparison with about 30-fold selectivity of BAY73-6691. Thus, our studies suggest that Tyr424, a unique residue of PDE8 and PDE9, is a potential target for improvement of selectivity of PDE9 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22985069      PMCID: PMC3469756          DOI: 10.1021/jm301189c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  46 in total

Review 1.  Phosphodiesterase inhibitors as potential cognition enhancing agents.

Authors:  Christopher J Schmidt
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

2.  The effect of phosphodiesterase inhibitors on the extinction of cocaine-induced conditioned place preference in mice.

Authors:  Shervin Liddie; Karen L Anderson; Andres Paz; Yossef Itzhak
Journal:  J Psychopharmacol       Date:  2012-05-16       Impact factor: 4.153

3.  Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.

Authors:  Huanchen Wang; Yudong Liu; Yuxiang Chen; Howard Robinson; Hengming Ke
Journal:  J Biol Chem       Date:  2005-07-01       Impact factor: 5.157

Review 4.  Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity.

Authors:  Hengming Ke; Huanchen Wang
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

Review 5.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.

Authors:  Marco Conti; Joseph Beavo
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

6.  Structural basis for the catalytic mechanism of human phosphodiesterase 9.

Authors:  Shenping Liu; Mahmoud N Mansour; Keith S Dillman; Jose R Perez; Dennis E Danley; Paul A Aeed; Samuel P Simons; Peter K Lemotte; Frank S Menniti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

7.  Crystallography & NMR system: A new software suite for macromolecular structure determination.

Authors:  A T Brünger; P D Adams; G M Clore; W L DeLano; P Gros; R W Grosse-Kunstleve; J S Jiang; J Kuszewski; M Nilges; N S Pannu; R J Read; L M Rice; T Simonson; G L Warren
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1998-09-01

Review 8.  Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.

Authors:  Andrew T Bender; Joseph A Beavo
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 9.  Molecular diversity of cyclic AMP signalling.

Authors:  F A Antoni
Journal:  Front Neuroendocrinol       Date:  2000-04       Impact factor: 8.606

Review 10.  Improving memory: a role for phosphodiesterases.

Authors:  A Blokland; R Schreiber; J Prickaerts
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

View more
  12 in total

1.  Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor.

Authors:  Manna Huang; Yongxian Shao; Jianying Hou; Wenjun Cui; Beibei Liang; Yingchun Huang; Zhe Li; Yinuo Wu; Xinhai Zhu; Peiqing Liu; Yiqian Wan; Hengming Ke; Hai-Bin Luo
Journal:  Mol Pharmacol       Date:  2015-08-27       Impact factor: 4.436

Review 2.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

3.  A novel PDE9 inhibitor WYQ-C36D ameliorates corticosterone-induced neurotoxicity and depression-like behaviors by cGMP-CREB-related signaling.

Authors:  Xian-Feng Huang; Wen-Tao Jiang; Li Liu; Fang-Chen Song; Xia Zhu; Gui-Lan Shi; Shu-Ming Ding; Heng-Ming Ke; Wei Wang; James M O'Donnell; Han-Ting Zhang; Hai-Bin Luo; Yi-Qian Wan; Guo-Qiang Song; Ying Xu
Journal:  CNS Neurosci Ther       Date:  2018-05-02       Impact factor: 5.243

Review 4.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

5.  Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.

Authors:  Yong-xian Shao; Manna Huang; Wenjun Cui; Ling-Jun Feng; Yinuo Wu; Yinghong Cai; Zhe Li; Xinhai Zhu; Peiqing Liu; Yiqian Wan; Hengming Ke; Hai-Bin Luo
Journal:  J Med Chem       Date:  2014-12-08       Impact factor: 7.446

6.  Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.

Authors:  Tao Su; Tianhua Zhang; Shishun Xie; Jun Yan; Yinuo Wu; Xingshu Li; Ling Huang; Hai-Bin Luo
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

7.  Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors.

Authors:  Xu-Nian Wu; Ya-Dan Huang; Jin-Xuan Li; Yan-Fa Yu; Zhou Qian; Chen Zhang; Yinuo Wu; Hai-Bin Luo
Journal:  Acta Pharm Sin B       Date:  2018-03-12       Impact factor: 11.413

8.  Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease.

Authors:  Chen Zhang; Qian Zhou; Xu-Nian Wu; Ya-Dan Huang; Jie Zhou; Zengwei Lai; Yinuo Wu; Hai-Bin Luo
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

9.  Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems.

Authors:  Dakshinamurthy Sivakumar; Sathishkumar Mudedla; Seonghun Jang; Hyunjun Kim; Hyunjin Park; Yonwon Choi; Joongyo Oh; Sangwook Wu
Journal:  Biomolecules       Date:  2021-05-10

10.  A convenient four-component one-pot strategy toward the synthesis of pyrazolo[3,4-d]pyrimidines.

Authors:  Mingxing Liu; Jiarong Li; Hongxin Chai; Kai Zhang; Deli Yang; Qi Zhang; Daxin Shi
Journal:  Beilstein J Org Chem       Date:  2015-11-06       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.